SCD and hepatocellular carcinoma: As shown before,26 when resminostat (1 μmol/l) was applied alone (i.e., in absence of MeV-SCD), it was found to inhibit zfp64 mRNA production quite effectively in all three human hepatoma cell lines at early time points, i.e., at 5 hours after addition of resminostat (Figure 5, blue bars).